Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Med Chem ; 67(19): 17855-17865, 2024 Oct 10.
Artigo em Inglês | MEDLINE | ID: mdl-39305244

RESUMO

The fluorescence high-throughput screening method is of importance for new antioxidant drug candidate discovery for the treatment of serious hepatorenal syndrome, which displayed an obvious upregulated peroxynitrite level. However, most of the current ONOO- probes possessed incomplete fluorescence quenching efficiency, which can result in non-negligible probe inherent fluorescence. Hence, we utilized the probe conjugated structure disruption strategy to construct hydrogenation phosphorus-substituted rhodamine (H-PRh) with "zero" probe inherent fluorescence character. Based on the precursor, a series of natural products were screened for identifying antioxidant drug candidates. Luteolin was screened out by activating the Sirt1-Nrf2-HO-1 signaling pathway to regulate the accumulation of ONOO- in the hepatorenal syndrome. Overall, the "zero" probe inherent fluorescence ONOO- sensor constructed here applies for a promising and versatile toolbox for illuminating the ONOO--related pathological process in the hepatorenal syndrome. Besides, this strategy of constructing highly sensitive sensors could serve as a valuable reference for further fluorescent probes.


Assuntos
Antioxidantes , Corantes Fluorescentes , Ensaios de Triagem em Larga Escala , Ácido Peroxinitroso , Ácido Peroxinitroso/análise , Antioxidantes/química , Antioxidantes/farmacologia , Humanos , Ensaios de Triagem em Larga Escala/métodos , Corantes Fluorescentes/química , Fator 2 Relacionado a NF-E2/metabolismo , Produtos Biológicos/química , Produtos Biológicos/farmacologia , Animais , Sirtuína 1/metabolismo , Heme Oxigenase-1/metabolismo , Rodaminas/química , Luteolina/química , Luteolina/farmacologia , Fluorescência , Transdução de Sinais/efeitos dos fármacos
2.
J Exp Clin Cancer Res ; 35(1): 90, 2016 06 06.
Artigo em Inglês | MEDLINE | ID: mdl-27267902

RESUMO

BACKGROUND: Glioma is one of the most common and aggressive primary malignant tumor in the brain. Accumulating evidences indicated that aberrantly expressed non-coding RNAs (ncRNAs), including long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), contribute to tumorigenesis. However, potential mechanisms between lncRNAs and miRNAs in glioma remain largely unknown. METHODS: Long non-coding RNA activated by TGF-ß (LncRNA-ATB) expression in glioma tissues and cells was quantified by quantitative reverse transcription-PCR. Glioma cell lines U251 and A172 were transfected with sh-ATB, miR-200a mimics, miR-200a inhibitors, after we assayed the cell phenotype and expression of the relevant molecules. Dual-luciferase reporter assay, RIP and a xenograft mouse model were used to examine the expression of sh-ATB and its target gene miR-200a. RESULTS: ATB is abnormally up-regulated both in glioma tissues and cell lines compared with normal brain tissues, and glioma patients with high ATB expression had shorter overall survival time. Knockdown of ATB significantly inhibits glioma malignancy, including cell proliferation, colony formation, migration, invasion in vitro, and the xenograft tumor formation in vivo. In addition, ATB was confirmed to target miR-200a, and miR-200a inhibition reversed the malignant characteristics of ATB knockdown on glioma cells. In particular, ATB may act as a ceRNA, effectively becoming a sink for miR-200a, thereby modulating the derepression of TGF-ß2. CONCLUSIONS: Our findings suggest that ATB plays an oncogenic role of glioma cells by inhibiting miR-200a and facilitating TGF-ß2 in glioma, thereby may represent a potential therapeutic target for the treatment of human glioma.


Assuntos
Neoplasias Encefálicas/genética , Glioma/genética , MicroRNAs/genética , RNA Longo não Codificante/genética , Regulação para Cima , Adolescente , Adulto , Idoso , Animais , Neoplasias Encefálicas/patologia , Linhagem Celular Tumoral , Movimento Celular , Proliferação de Células , Feminino , Regulação Neoplásica da Expressão Gênica , Glioma/patologia , Humanos , Masculino , Camundongos , Pessoa de Meia-Idade , Invasividade Neoplásica , Transplante de Neoplasias , Prognóstico , Fator de Crescimento Transformador beta2/genética , Adulto Jovem
3.
ACS Appl Mater Interfaces ; 4(4): 2242-9, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22448881

RESUMO

Layered double hydroxides (LDHs) are generally expressed as [M(2+)(1-x)M(3+)(x) (OH)(2)] [A(n-)(x/n)·mH(2)O], where M(2+) and M(3+) are divalent and trivalent metal cations respectively, and A is n-valent interlayer guest anion. Co-Al layered double hydroxides (LDHs) with different sizes have been grown on graphene oxide (GO) via in situ hydrothermal crystallization. In the synthesis procedure, the GO is partially reduced in company with the formation of Co-Al LDHs. The morphology and structure of LDHs/GO hybrids are characterized by transmission electron microscopy (TEM), scanning electron microscopy (SEM), X-ray diffraction (XRD), X-ray photoelectron spectroscopy (XPS) and Raman spectroscopy. The growth mechanism of LDHs on GO nanosheets is discussed. Moreover, both LDHs and LDHs/graphene nanosheets (GNS) hybrids are further used as electrochemical supercapacitor materials and their performance is evaluated by cyclic voltammetry (CV) and galvanostatic charge/discharge measurements. It is shown that the specific capacitances of LDHs are significantly enhanced by the hybridization with GNS.

SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa